NCT00192296 - Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

February 28, 2005

Study Completion Date

March 31, 2005

Conditions

Asthma

Interventions

BIOLOGICAL

MEDI-528 0.3 mg/kg

MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose

BIOLOGICAL

MEDI-528 1 mg/kg

MEDI-528 (1 mg/kg) administered as a single, IV dose

BIOLOGICAL

MEDI-528 3 mg/kg

MEDI-528 (3 mg/kg) administered as a single, IV dose

BIOLOGICAL

MEDI-528 9 mg/kg

MEDI-528 (9 mg/kg) administered as a single, IV dose

Trial Locations (1)

MDS Pharma Services, New Orleans